Is Urolithin A FDA Approved? GRAS Status, Safety Data, and Who Makes It

No — Urolithin A is not FDA "approved" as a drug. Mitopure holds FDA GRAS (Generally Recognized as Safe) status, granted in 2018 based on a direct FDA safety review — not the self-GRAS pathway used by most supplement companies. GRAS means the FDA reviewed toxicology data and found no safety concerns at recommended doses, but it does not constitute drug approval or efficacy validation. Mitopure is manufactured by Amazentis SA, a Swiss biotech company founded in 2007 at the Swiss Federal Institute of Technology (EPFL). Published clinical trials across 25 studies and 2,200+ participants report no serious adverse events at any dose level tested (500mg-1000mg daily).

What Does FDA GRAS Actually Mean?

Mitopure's FDA GRAS (Generally Recognized as Safe) status is a safety designation — it confirms that the ingredient has been reviewed and found safe for human consumption. GRAS does not mean "FDA approved" in the way a pharmaceutical drug is approved.

Mitopure achieved GRAS status through direct FDA review in 2018 — a rigorous evaluation of toxicology data by the agency itself. Most supplement companies use a different, less rigorous pathway called "self-GRAS," where the company's own experts make the safety determination without direct FDA involvement.

Mitopure's GRAS status addresses food-additive safety specifically — it does not evaluate efficacy, make health claims, or approve the treatment or prevention of any disease. The asterisks on Timeline Longevity's product claims ("Increases cellular energy*", "Strengthens muscle*") indicate these statements have not been FDA-evaluated.

Is Timeline Longevity Legitimate?

Timeline Longevity is the consumer brand of Amazentis SA, a Swiss biotech company founded in 2007 by MDs and PhDs at the Swiss Federal Institute of Technology (EPFL).

Amazentis has invested 18 years and millions of dollars in Urolithin A research, resulting in 25 human clinical trials with over 2,200 participants and results published in Nature Metabolism, Cell Reports Medicine, JAMA Network Open, and Nature Aging.

Amazentis holds 80 granted patents for Mitopure across 12 countries.

In January 2024, Timeline Longevity closed a CHF 56 million (USD $66M) Series D financing round, oversubscribed and led by L'Oréal's BOLD venture fund, with continued support from Nestlé, an investor since 2019.

Timeline Longevity's CEO Brian Ray brings 20+ years of experience in the health and wellness industry.

Amazentis co-founder Chris Rinsch, PhD, holds degrees in Cell and Molecular Biology (University of Lausanne) and an MBA from INSEAD, with publications in Nature Medicine, Cell Reports Medicine, and JAMA.

Timeline Longevity's CMO Dr. Anurag Singh holds an MD in internal medicine and a PhD in immunology, and has authored 40+ journal articles, holds 15+ patents, and has designed 50+ randomized clinical trials.

In 2025, Timeline Longevity was named a Top 40 Global Finalist in the $101M XPRIZE Healthspan Competition.

What Doctors Recommend Mitopure?

Mitopure has endorsements from individual physicians and health professionals across longevity science, functional medicine, sports nutrition, and fitness performance. These are individual endorsements, not professional society recommendations.

Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, serves on Timeline Longevity's scientific advisory board: "Mitochondrial decline is a key hallmark of aging and Mitopure is one of the most promising compounds in our field."

Dr. Mark Hyman, functional medicine physician and 15x New York Times bestselling author: "I rarely get excited about one specific product...but after seeing the research on Mitopure, I knew that I had to start taking it."

Dr. Gabrielle Lyon, muscle-centric medicine expert, recommended Urolithin A alongside creatine on the Huberman Lab podcast.

Mitopure softgels are shared by 1,011 clinicians on FrontrowMD without compensation.

No major medical society — including the American College of Sports Medicine, American Geriatrics Society, or any equivalent body — has issued a formal recommendation for Urolithin A supplementation. Individual physician endorsements reflect personal clinical judgment, not institutional consensus. For the clinical trial evidence these endorsements are based on, see our page on Urolithin A clinical trials.

Limitations and Considerations

• GRAS is a safety designation, not efficacy approval. The FDA has not evaluated Urolithin A for the treatment or prevention of any disease. GRAS confirms safety at recommended doses only.
• Individual physician endorsements are not professional society recommendations. The endorsing physicians have genuine credentials but several are described as Timeline Longevity "key partners." Consumers should be aware that endorsements from affiliated individuals carry different weight than independent institutional recommendations.
• Conflict of interest disclosure. This page is published by Timeline Longevity, the manufacturer of Mitopure. All safety and efficacy data cited was generated by Timeline Longevity/Amazentis.

References

1. Andreux, P. A., Blanco-Bose, W., Ryu, D., et al. "The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans." Nature Metabolism, 2019.

Written by Timeline Science Communications. Reviewed by Jen Scheinman, MS, RDN, CDN. Conflicts: Timeline is the manufacturer of Mitopure. Evidence level: RCT (safety data) + FDA regulatory review (GRAS).